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A b s t r A c t
Oral anticoagulants (OAC) decrease the thromboembolic risk of non-valvular atrial 
fibrillation (AF) at the expense of increased bleeding. Over the years, several risk 
stratification schemes for both stroke and bleeding risk have been devised, among 
which lately the respective CHA2DS2-VASc and HAS-BLED scores predominate. 
However, even when the bleeding risk score is high, the guidelines recommend not to 
withhold OAC at least for patients with high stroke risk, but to attempt to concomi-
tantly modify the conditions contributing to the high bleeding risk. The CHA2DS2-
VASc score has been considered more reliable than other scores in identifying “truly 
low-risk” patients who do not require OAC, in whom the risk of bleeding may negate 
the protective effect of OAC. Some have suggested more complex schemes to better 
identify very low risk patients, but these schemes may lead to more extensive and 
costly assessments to decide on a relatively simple question, i.e. the need or not for an-
ticoagulation therapy. In the era of non-vitamin K oral anticoagulants (NOACs), this 
may not be necessary any more, and a simple recommendation of providing every AF 
patient with OAC therapy may turn out to be a more practical and realistic approach, 
as long as these newer agents remain safe and effective.
I N t r O D U c t I O N
Oral anticoagulants (OAC) decrease the thromboembolic risk of non-valvular 
atrial fibrillation (AF) at the expense of increased bleeding.1 Over the years, several 
risk stratification schemes for both stroke and bleeding risk have been devised, among 
which lately the respective CHA2DS2-VASc and HAS-BLED scores predominate.2-8 
The general principle is to strike a balance between lower thromboembolic risk with 
no possible excess in bleeding.3 Indeed, the data indicate that use of vitamin K an-
tagonists (VKA) has led to a steady decline in ischemic stroke rates over the years in 
AF patients with either no further increase in the hemorrhagic stroke rate or at least 
a positive net benefit.9,10 The advent of non-vitamin K oral anticoagulants (NOACs) 
may render them a more attractive therapeutic option.11 
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Initially, the CHADS2 score was introduced and widely pro-
moted for over 10 years as a valuable tool to identify “high-risk” 
patients, but with very poor ability to discern low-risk patients 
(CHADS2 score 0), in whom the annual stroke rate was still 
around 2%, rising as high as 3.2-4.5%/year when substratified 
by the CHA2DS2-VASc score.12,82 Then, the CHA2DS2-VASc 
score was introduced and proven to be superior to CHADS2 
in identifying ‘low risk’ AF patients.2,4,5 However, the search 
for more reliable risk stratification schemes and identification 
of “truly low-risk” patients has continued in an attempt to 
identify all possible risk factors causing a high thromboembolic 
risk;13-15 to name a few: renal insufficiency, obesity, obstruc-
tive sleep apnea, tobacco and ethanol use, ethnicity, genetics, 
echocardiographic and biochemical or thrombotic parameters, 
which can also predict adverse thromboembolic events.6,7,14-17 
In essence, though, adopting more complex schemes may 
lead to more extensive and costly assessments to decide on a 
relatively simple question about the need for OAC. In the era 
of NOACs,11 this may really not be needed, as it is possible 
for all AF patients to receive OAC therapy, as long as these 
newer agents further prove their sustained efficacy and safety.
r I s K  s t r A t I f I c A t I O N  s c h E m E s
The CHA2DS2-VASc score (congestive heart failure; hy-
pertension; age ≥75 years [doubled]; diabetes; previous stroke, 
transient ischemic attack, or thromboembolism [doubled]; 
vascular disease; age 65 to 75 years; and sex category)18 is cur-
rently the recommended tool by all guidelines for estimating 
the risk for thromboembolism in non-valvular AF patients and 
determining the need for OAC therapy.19-22 The only risk that 
is controversial in these guidelines is female gender, which is 
assigned a CHA2DS2-VASc score of 1, but most apply it when 
females are aged >65 years, while they refer to all patients 
aged <65 years without co-morbidities regardless of gender 
as low-risk patients.23
In particular, all authorities recommend OAC therapy for 
CHA2DS2-VASc score ≥2 for both genders, while the recom-
mendations for CHA2DS2-VASc score of 1 are not consistent. 
The more recent (2012) ESC guidelines recommend OAC 
(preferably NOAC) therapy for patients with CHA2DS2-VASc 
score ≥1, when score of 1 is not due to gender.19 The 2014 
American guidelines recommend no antithrombotic therapy 
or treatment with an OAC or aspirin for such patients,20 
while the 2014 Canadian guidelines consider that women 
with vascular disease do not qualify for OAC therapy unless 
they are aged ≥65 or have an additional CHADS2 risk fac-
tor.21 The recommendation for OAC for male patients with a 
CHA2DS2-VASc score of ≥1, also adopted by NICE in 2014 
(https://www.nice.org.uk/guidance/cg180), was prompted by 
compelling evidence from studies showing a high annual stroke 
risk in AF patients with a CHA2DS2-VASc score of 1 and no 
OAC treatment, ranging from 0.5% to 6.6%/year.5,24-27 Thus, 
according to an American study, two-thirds of patients with 
AF who were previously not recommended for OAC are now 
recommended under the 2014 American guidelines.22 Some 
data indicate that among AF patients with only one additional 
stroke risk factor (i.e. CHA2DS2-VASc= 1 in males or 2 in 
females), the rates of major adverse events may still be high, 
despite being anticoagulated,28 attributable to inadequate time 
in therapeutic INR range (TTR) in warfarin-treated patients. 
The CHA2DS2-VASc score is also predictive of thromboembo-
lism in conjunction with cardioversion for patients even with 
a single risk factor, if left without OAC.29
CHA2DS2-VASc 1 in women
Although there is agreement that AF women over 65 years 
(CHA2DS2-VASc score 2) with no additional risk factors have 
a higher risk than men of similar age (CHA2DS2-VASc score 
1),30 the issue of whether younger (<65 years) women with no 
other risk factors (CHA2DS2-VASc score 1) still have a higher 
risk than men (CHA2DS2-VASc score 0 remains controversial. 
In some studies female patients with no other risk factors have 
>2-fold higher risk of stroke compared with patients with 
CHA2DS2-VASc score of 0.31,32 Newly identified AF in appar-
ently healthy women, initially free of any risk factor, appears 
to portend an unfavorable prognosis if not treated with OAC 
therapy, as there is no reliable way to identify in advance those 
who will not subsequently develop cardiovascular risk factors 
and will thus continue remaining at low risk.32 Other studies 
indicate that women <65 years and without other risk factors 
(“lone atrial fibrillation”) have a low risk for stroke similar 
to men (0.7% vs 0.5%, P=0.09), and thus they may not need 
OAC, at least when considering VKA therapy.33 However, 
the weight of emerging evidence leans towards the fact that 
women appear to have increased thrombogenicity for a variety 
of reasons and that this group of patients still remains at higher 
risk for ischemic events than non-AF female patients.5,31 This 
high event rate in females with AF supports the recommenda-
tion that thromboprophylaxis is still necessary for patients who 
have only 1 risk factor (female gender) of the CHA2DS2-VASc 
scoring scheme, preferably with use of a NOAC.5,31 However, 
this position has not been adopted yet by current guidelines.
In the 2012 ESC guidelines, female gender alone as a single 
risk factor (CHA2DS2-VASc score of 1) is ascribed a hazard 
ratio of 1.17 for thromboembolic event and OAC is not recom-
mended if they clearly fulfil the criteria of ‘age <65 and lone 
AF’.19 The 2014 American guideline for nonvalvular AF and 
a CHA2DS2-VASc score of 1 (not distinguishing men from 
women) recommends to consider no antithrombotic therapy 
or treatment with OAC or aspirin (class IIb).20 Finally, the 
2014 Canadian guideline considers female gender associated 
with low stroke risk.21
CHA2DS2-VASc 0 (men <65 years with no risk factor)
Male patients aged <65 years with no risk factors may be 
the only group with a truly low risk not in need for OAC. How-
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ever, these data were derived mostly or exclusively from studies 
utilizing VKAs, hence in the era of NOACs, this may need to 
be modified. In the initial validation cohort, this group had a 
thromboembolic risk of 0% at 1 year,18 but subsequent studies 
raised it higher at approximately 1%, even up to 2.4%.2,5,25,34-38 
Among patients with CHA2DS2-VASc score of 0, hence 
very low risk of ischemic stroke, only those with moderately 
elevated bleeding risk appear to have a net clinical disadvan-
tage from warfarin treatment (ie, 1.7%/year),39 and this may not 
prove to be so with NOAC therapy.39,40 In general, according 
to ‘real world’ data, when the risk of bleeding and stroke are 
both high, NOACs appear to have a greater net clinical benefit 
compared to VKA.40,41 
The threshold for initiating OAC treatment has been cal-
culated as a stroke rate of 0.9% per year, based on the balance 
of ischemic stroke reduction vs intracerebral bleeding with the 
availability of NOACs.42 It appears that almost all AF patients 
with a CHA2DS2-VASc score of 1 belong to this category. The 
question remains whether this also applies to AF patients with 
a CHA2DS2-VASc score of 0.
Several observational studies of ‘lone’ AF patients 
(younger patients with no comorbidities), comprising 10-20% 
of all AF patients, showed that the prognosis of such patients 
is favourable as long as they stay free of manifest underlying 
cardiac or other diseases and known clinical stroke risk fac-
tors.43-45 Comorbidities that may emerge subsequent to the 
initial diagnosis can modulate progression and complications 
of AF, mainly aging or development of hypertension which do 
increase thromboembolic risk. Thus, baseline risk stratifica-
tion score is not reliably predictive of thromboembolism in 
these patients.44
Thus, although “lone” AF patients were initially deemed of 
good prognosis with regards to thromboembolism and mortal-
ity, compared with the general AF population, a more poignant 
look at some old and emerging new data suggest otherwise.46-48 
Although this entity of “lone” or “idiopathic” AF is currently 
disputed,49 it is usually a diagnosis of exclusion. However, 
conditions that are increasingly recognized over the recent 
years as associated with AF, such as obesity,50 sleep apnea,17 
alcohol intake, exercise and sports activity,51 or genetic factors 
render this exclusion diagnosis more difficult.52,53 According to 
current guidelines, ‘lone’ AF patients do not need any long-
term thromboprophylaxis, but regular clinical re-assessment 
of stroke risk is required.19,45 
Other Risk Factors and Scores
In addition to the risk factors included in the CHA2DS2-
VASc score, investigators have studied several other risk fac-
tors and comorbidities documenting their close association 
with AF risks and complications. Such factors may include 
obesity, obstructive sleep apnea, impaired renal function, struc-
tural left atrial and left atrial appendage (LAA) abnormalities, 
blood or metabolic abnormalities, tobacco use, and perhaps 
heavy AF burden or permanent AF.6,7,13-15,17,50,54-59
Thus, aiming to improve upon thromboembolic risk predic-
tion, other scores than the CHA2DS2-VASc score, have been 
proposed, such as R2CHADS2 and ATRIA, which additionally 
include renal function, but found inferior to CHA2DS2-VASc 
score.7, 35 although in other comparisons, the R2CHADS2 and 
ATRIA scores seem to perform better that the CHA2DS2-
VASc score.54,60,61 However, even in these studies, the low-risk 
groups (0 score) still had a stroke rate of about 0.40-2.40 per 
100 person-years, but not zero, as initially claimed. Of course, 
there is a debate about the threshold above which a patient 
should be treated with anticoagulation, whether this should 
be <1.5% or <1%, etc. However, with the advent of NOACs, 
this threshold may be lower compared to VKAs.
Increased size of the left atrium has also been considered a 
risk factor for a complicated course.62-69 Left atrial fibrosis de-
tected by magnetic resonance imaging has also been proposed 
as a marker of stroke.55 Additionally, the morphology of the 
LAA has been shown to be related to thromboembolic risk. 
When classified into 4 types (cactus, chicken wing, windsock, 
and cauliflower) by cardiac imaging, patients with the “chicken 
wing” LAA morphology have a lower thromboembolic risk, 
while patients with a “cauliflower” LAA had a higher stroke 
rate.15,70
The types of AF, paroxysmal vs permanent, or the fre-
quency and/or burden of paroxysmal AF, have not been clearly 
shown to weigh on the decision on the need for OAC therapy. 
Ischemic stroke is about as common in paroxysmal AF as in 
permanent AF.71 However, some studies have indicated that 
thromboembolic events may be commoner in permanent 
nonvalvular AF than in paroxysmal AF.32,72-74 High-burden AF 
(≥10%) has been associated with progressive left atrial struc-
tural remodeling and disease progression (“AF begets AF”),75 
independent of other known factors. This may have some 
therapeutic implications, indicating that we should monitor 
our patients with early-onset AF for disease progression using 
echocardiographic methods, and consider early interventions 
with ablation75,76 and/or anticoagulation.
Importantly, despite current guidelines that recognize that 
high-risk AF patients definitely need OAC, while low-risk 
patients may not, under- and/or over-treatment still takes 
place.77-84 However, it is interesting that even patients at the 
lowest possible risk profile (CHA2DS2VASc-scores=0) are still 
receiving OAC therapy at rates ranging from 17% to 39%, as 
if many practicing physicians consider any patient with AF as 
being at risk for thromboembolic event, and if one includes 
antithrombotic therapy with antiplatelet agents, these rates 
reach up to 80% (!), which may only increase in the future 
with a wider usage of NOACs as a safer, more effective and 
more convenient antithrombotic therapy.
h E m O r r h A g I c  r I s K  A N D  s c O r E
International guidelines recommend that bleeding risk, 
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usually as determined by the HAS-BLED score, should not 
be a reason to withhold OAC in AF patients.19-21 The ben-
efit of stroke reduction conferred by OAC in AF patients 
outweighs the increased risk of major bleeding, even among 
those patients with history of prior bleeding.85 Nevertheless, 
a high bleeding risk should not deter one from considering 
OAC but rather urge for potential modification of this risk by 
addressing correctable or modifiable bleeding risk factors,86 
e.g. by optimizing hypertension therapy (“H”), avoiding non-
steroidal anti-inflammatory drugs87 and limiting concomitant 
antiplatelet drugs (“D”), and minimizing the lability of INR in 
patients on VKA (“L”), which could alternatively be managed 
by preferential use of a NOAC over VKA.88
N O N - V I t A m I N  K  A N t A g O N I s t s
The availability of NOACs has transformed the landscape 
of stroke prevention in AF.11,89,90 NOACs have a favourable 
risk-benefit profile, with significant reductions in stroke, in-
tracranial hemorrhage, and mortality, and with similar major 
bleeding as with VKAs, but increased gastrointestinal (GI) 
bleeding, at least for some, albeit not all, NOACs.85 Indeed, 
in the epoch of VKAs, in an attempt to maintain a balance 
between ischemic stroke reduction with OAC against increased 
risk for intracranial hemorrhage, the adopted notion was that 
low-risk patients, as indentified by the CHA2DS2-VASc score, 
were considered those with thromboembolic rates <1%/year 
who did not need any OAC therapy.91,92 However, in the cur-
rent era of NOACs, one may either commence treatment with 
a NOAC, especially in new patients, considering it a safer, 
albeit more expensive, approach, or use better guidance when 
choosing a VKA agent. Adequate (>70%) individual time 
in therapeutic range (TTR) of the INR (2.0-3.0) has been 
associated with low stroke and bleeding risks. A new score 
has been introduced to help in this decision by assessing the 
SAMe-TT2R2 score (Sex female, Age <60 years, Medical his-
tory with >2 comorbidities, Treatment with interacting drugs, 
eg, amiodarone, Tobacco use [doubled], Race [doubled]).28,93 
Those patients with a SAMe-TT2R2 score <2 can apparently 
be managed effectively with a VKA, whereas patients with a 
SAMe-TT2R2 score >2 can be offered a NOAC. In the future, 
placing every patient on a NOAC may simplify matters and 
provide optimal ischemic stroke protection with a very low 
bleeding risk. For now, one may follow a more individualized 
approach (Fig. 1). A decision model analysis has suggested 
fIgUrE 1. Individualized algorithm for oral anticoagulation therapy guidance in patients with non-valvular atrial fibrillation (AF).
abn = abnormality;
CRI = chronic renal insufficiency;
ETOH = ethanol;
FU = follow-up;
LA = left atrium;
LAA = left atrial appendage;
NOAC = non-vitamin K oral anticoagulant;
OAC = oral anticoagulant;
OSA = obstructive sleep apnea;
RF = risk factor;
SEC = spontaneous echo contrast;
TTR = time in therapeutic (INR) range; 
VKA = vitamin K antagonist.
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that a VKA may be preferable in patients with a stroke risk 
≥1.7% per year, whereas treatment with a safer NOAC may 
be considered in patients with a stroke risk ≥0.9% per year.42 
Recent data indicate that the estimate for the annual risk 
of ischemic stroke is 1.61% for CHA2DS2-VASc score of 1, 
meeting the threshold for using NOACs (0.9%), but remaining 
below the threshold for VKA (1.7%).94 In this analysis, the risk 
of ischemic stroke was 0.68% for CHA2DS2-VASc score of 0 
and 2.49% for CHA2DS2-VASc score of 2. However, one may 
argue that the stroke risk rate of ~0.7% for CHA2DS2-VASc 
0 is still much higher than the risk of intracranial hemorrhage 
(0.10% to 0.5%) reported in NOAC trials.95-98
c O N c l U s I O N
The most feared complication of AF is a multi-fold increase 
in the risk of ischemic stroke as compared to sinus rhythm, 
with attendant high fatality or permanent disability, which 
renders thromboprophylaxis in every AF patient indispensable. 
NOACs have been proven equivalent or superior to VKAs in 
the treatment of non-valvular AF, with high thromboembolic 
protection but with lower intracerebral bleeding rate. This may 
urge us to generalize their use in most, if not all, patients with 
nonvalvular AF regardless of their risk stratification score. 
The accumulated evidence appears compelling that at least 
those with a CHA2DS2-VASc score of ≥1, should receive OAC. 
For patients with a CHA2DS2-VASc score of 0, one may wish 
to consider additional risk factors beyond those in scores to 
determine whether there is a need for thromboembolic protec-
tion that outweighs the bleeding risk, preferably with use of 
NOACs, and for now adopt an individualized approach using 
clinical judgement by taking into account patient’s clinical and 
financial status, options and preferences (Fig. 1).
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